Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri, USA.
Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
Am J Gastroenterol. 2022 Apr 1;117(4S):S6-S13. doi: 10.14309/ajg.0000000000001687.
Multiple therapeutic agents are currently available for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. A better understanding of the mechanism of action of each treatment provides important insights into expected responses and is key to optimizing treatment outcomes. Some constipation treatments, such as stimulant laxatives, may increase bowel movement frequency but are ineffective at relieving, and may even exacerbate, abdominal symptoms. On the contrary, prescription treatments, such as the guanylyl cyclase-C agonists, for example, may improve bowel symptoms and reduce visceral hypersensitivity. This review summarizes the mechanisms of action of commonly used over-the-counter and prescription therapies for chronic idiopathic constipation and irritable bowel syndrome with constipation, outlining how these mechanisms contribute to the efficacy and safety of each treatment option.
目前有多种治疗药物可用于治疗慢性特发性便秘和便秘型肠易激综合征。更好地了解每种治疗方法的作用机制可以提供对预期反应的重要见解,是优化治疗效果的关键。一些便秘治疗药物,如刺激性泻药,可能会增加排便频率,但对缓解腹部症状无效,甚至可能加重这些症状。相反,一些处方治疗药物,如鸟苷酸环化酶-C 激动剂,可能会改善肠道症状并降低内脏敏感性。本综述总结了常用于慢性特发性便秘和便秘型肠易激综合征的非处方和处方治疗药物的作用机制,概述了这些机制如何有助于每种治疗选择的疗效和安全性。